Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma
Status:
Completed
Trial end date:
2006-02-01
Target enrollment:
Participant gender:
Summary
The main objective of this study is to assess the long-term effectiveness of SCIO-469 as
monotherapy, or in combination with bortezomib in relapsed, refractory patients with multiple
myeloma (MM) who have previously demonstrated clinical benefit in the Scios B003 study.